{"id":1565,"date":"2019-02-26T00:00:00","date_gmt":"2019-02-25T22:00:00","guid":{"rendered":"http:\/\/interchem.epicstation.com\/news\/informacionnoe-obraschenie-otnositelno-preparata-amispiron-%d0%86s\/"},"modified":"2019-02-26T00:00:00","modified_gmt":"2019-02-25T22:00:00","slug":"informacionnoe-obraschenie-otnositelno-preparata-amispiron-Is","status":"publish","type":"news","link":"https:\/\/interchem.ua\/en\/news\/informacionnoe-obraschenie-otnositelno-preparata-amispiron-Is\/","title":{"rendered":"Information appeal regarding to the drug Amispiron IC"},"content":{"rendered":"

The Pharmacovigilance Risk Assessment Committee EMA (PRAC) recommended temporarily<\/a> to stop <\/span><\/span>using<\/span><\/span>drugs containing fenspiride<\/span><\/span>.<\/span><\/span><\/span><\/p>\n

Suspension is a precautionary measure to protect patients during PRAC review of evidence of the risk of prolonged QT interval and torsades de pointes (disturbances in the electrical activity of the heart, which may lead to disturbances in the heart rhythm).<\/span><\/span><\/span><\/span><\/p>\n

On the basis of PRAC data and in accordance to<\/span><\/span> the legislation of Ukraine, the State Drugs and Medication Central Service<\/span><\/span> of Ukraine temporarily stop<\/span><\/span> the sale and use<\/a> of all series of drugs which<\/span><\/span> contain the active substance fenspiride,<\/span><\/span><\/span><\/p>\n

including,<\/span><\/em><\/span><\/span><\/span><\/p>\n

AMISPIRON \u0406\u0421, long-acting tablets of 0.08 g \u211610 and \u211620, production of “INTERCHEM” <\/span>SLC<\/span><\/span>, Ukraine,<\/span><\/em><\/span><\/span><\/span><\/p>\n

until the end of the PRAC audit and the decision of the European Medicines Agency (EMA) on the conditions for the continuation or withdrawal of a marketing authorisation<\/span> for the circulation of medicines containing fenspiride.<\/span><\/span><\/span><\/span><\/p>\n

According to the State Drugs and Medication Central Service<\/span> of Ukraine in identifying samples of this medicinal product, the company must take measures to:<\/span><\/span><\/span><\/span><\/p>\n